Covered recipient · General Payments record
ERIC J LUK
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$11,191.17
- Reported across 110 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $1,250.00 | 3 |
| Food and Beverage | $987.35 | 49 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $1,070.86 | 3 |
| SOBI, INC | $256.26 | 4 |
| Janssen Biotech, Inc. | $143.46 | 10 |
| PFIZER INC. | $86.45 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $82.63 | 4 |
| Takeda Pharmaceuticals U.S.A., Inc. | $75.95 | 3 |
| Merck Sharp & Dohme Corporation | $46.81 | 2 |
| Daiichi Sankyo Inc. | $46.48 | 2 |
| EISAI INC. | $42.04 | 2 |
| Astellas Pharma US Inc | $41.78 | 2 |
| GENZYME CORPORATION | $40.97 | 1 |
| E.R. Squibb & Sons, L.L.C. | $34.13 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $32.78 | 1 |
| GlaxoSmithKline, LLC. | $32.10 | 1 |
| Alexion Pharmaceuticals, Inc. | $28.00 | 2 |
| Celgene Corporation | $24.77 | 1 |
| Mirati Therapeutics, Inc. | $23.66 | 1 |
| Incyte Corporation | $22.59 | 1 |
| Genmab U.S., Inc. | $22.18 | 1 |
| ADC Therapeutics America, Inc. | $18.49 | 1 |
| Genentech USA, Inc. | $17.85 | 1 |
| ABBVIE INC. | $17.15 | 1 |
| Karyopharm Therapeutics Inc. | $15.22 | 1 |
| Apellis Pharmaceuticals, Inc. | $14.74 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (52)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.